Skip to search formSkip to main contentSkip to account menu

Solitomab

Known as: Anti-EpCAM BiTE 
A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Bispecific

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
2014
2014
Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
2014
2014
535 Tumor targeting and tissue distribution of solitomab (AMG 110; anti-EpCAM BiTE®) in human EpCAM-positive tumor bearing mice
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)